Daily Brief Health Care: Alebund Pharmaceuticals Jiangsu, BillionToOne, Evommune, Shofu Inc, GSK , Hugel Inc, Veritas In Silico, NanoViricides , Revelation Biosciences , SUSMED and more

• Alebund Pharmaceuticals, a China-based clinical-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. Jefferies, BoA, and HTSC are the joint sponsors.
• In this note, we look at the company’s history and its core product, AP301, and AP306.
• We are of the view that the company is worth following.

• BillionToOne priced above range at $60.00 and opened at $100.00, closing up 81.6% at $108.94.
• The deal was more than 20x oversubscribed, driven by strong long-only and healthcare demand
• Backed by top-tier investors and partnerships with Johnson & Johnson, BLLN’s profitability and precision platform stood out in a choppy IPO market.

• Evommune (EVMN) priced at $16.00 and opened at $17.25, closing its debut session above issue, outperforming expectations with steady aftermarket support.
• The IPO was led by long-only and healthcare-dedicated investors, signaling conviction in the company’s focused dermatology pipeline.
• Backing from RA Capital and a strong Phase 2 data set for EVO756 reinforce credibility and set the stage for continued positive momentum.

• Revenue reached JPY19.1bn (+1.1% YoY), with domestic revenue up 4.5% and overseas revenue down 1.2% YoY.
• Operating profit decreased 7.5% YoY to JPY2.8bn, while net income attributable to owners increased 9.9% YoY to JPY2.6bn.
• Dental business revenue rose 1.5% YoY; Nail Care business saw a 5.3% YoY decline in revenue.

• GSK reported strong results for the third quarter of 2025, with total sales increasing by 8% year-over-year, driven largely by growth in specialty medicines.
• Core operating profit improved by 11%, while earnings per share (EPS) rose by 14%.
• These results led GSK to upgrade their full-year guidance for both sales and profits, reflecting ongoing momentum in their core business areas.

• Hugel Inc (145020 KS) has reported muted 3Q25 result, with flat revenue and profits decreasing compared to year-ago period. Domestic revenue decreased 19% YoY and dragged overall 3Q25 result.
• However, strong export revenue of botulinum toxin and dermal fillers is the key bright spot in 3Q25 result. During 3Q25, international revenue grew 12% YoY.
• Since declaring 2Q result, Hugel shares plunged ~40%. More downside cannot be ruled out. 4Q result showing recovering domestic business and improved profitability under new leadership should be near-term catalyst.     

Key points (machine generated)

• Veritas In Silico Inc. specializes in mRNA-targeted drug discovery using its ibVIS® platform for developing small molecule and nucleic acid drugs.
• The company employs a hybrid business model, collaborating with pharmaceutical firms while also maintaining an in-house drug development pipeline.
• Despite a revenue decline in the first half of FY12/25, Veritas expects significant growth in the latter half, driven by milestone payments and new contracts.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.

• NanoViricides, Inc. (NNVC) is a clinical-stage company that is developing NV-387, a novel antiviral compound that will be initiating a clinical trial against MPox in late 2025/early 2026, with multiple other potential anti-viral indications.
• Preclinical results show that NV-387 possesses anti-viral activity against a wide range of pathogens, including respiratory syncytial virus (RSV), influenza, and measles.
• The company will be filing a clinical trial authorization (CTA) in order to conduct a Phase 2 clinical trial for the treatment of MPox in the Democratic Republic of Congo.

• Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system.
• The company released 3Q2025 financials and showed good cash on hand.
• This will allow the company to advance previously announced test results for its Gemini product that were so good the Primary Investigator called them “shocking.” This bodes well for the future of REVB as it looks toward commercialization.

Key points (machine generated)

• SUSMED, Inc. focuses on digital therapeutics, with a notable insomnia app approved for partial changes and insurance coverage request in September 2025.
• The company operates in two segments: DTx Product for therapeutic app development and DTx Platform for enhancing clinical trial efficiency.
• In FY6/25, SUSMED saw a 35.1% increase in operating revenue to ¥462 million, but FY6/26 forecasts are uncertain due to pending insurance reimbursement details.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.